Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment - de Jong, Jan; Skee, Donna; Hellemans, Peter; Jiao, James; de Vries, Ronald; Swerts, Dominique; Lawitz, Eric; Marbury, Thomas; Smith, William; Sukbuntherng, Juthamas; Mannaert, Erik (Leukemia & lymphoma, 2017)
Keywords: Adult; Aged; Area Under Curve; Biomarkers; Drug Monitoring; Female; Hepatic impairment; Humans; ibrutinib; Incidence; Liver Diseases - blood; Liver Diseases - complications; Liver Diseases - diagnosis; Liver Diseases - epidemiology; Liver Function Tests; Male; Middle Aged; Neoplasms - blood; Neoplasms - complications; Neoplasms - drug therapy; pharmacokinetic; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - pharmacokinetics; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrazoles - pharmacokinetics; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - pharmacokinetics; safety; Severity of Illness Index; ibrutinib; Hepatic impairment; pharmacokinetic; safety